Zenocutuzumab
Based on 2 publication(s) in Google Scholar
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.9%
- CAS. Nr.: 1969309-56-5
- Molecular Weight:145.76 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Zenocutuzumab
MoreAlle EGFR Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
ERBB2/HER2/CD340
In Vitro
Zenocutuzumab (0.001-1000 nM; 96 hours) inhibits cell growth in lung and breast cancer cell lines[1].
Zenocutuzumab (0.1-1000 nM; 24 hours) inhibits HER3 and AKT phosphorylation, induces markers of apoptosis and cell cycle arrest in lung and breast cancer cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
-
Cell Line:Human bronchiolar epithelial cell lines (HBEC)
-
Concentration:0.001 nM, 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM
-
Incubation Time:96 h
-
Result:Reduced the growth of isogenic HBEC expressing either CD74-NRG1 or VAMP2-NRG1 fusions.
-
Cell Line:HBEC-CD74-NRG1, LUAD-0061AS3, MDA-MB-175-VII cells
-
Concentration:0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM
-
Incubation Time:24 hours
-
Result:Inhibited HER3, STAT3, AKT, p70S6K, and S6 phosphorylation.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:6 to 12-week-old female NSG™ (LUAD-0061AS3), BALB/c nude (OV-10–0050) or athymic nude (ST2891, ST3204 and CTG-0953) mice injected with NRG1 fusion-positive patient-derived xenograft (PDX) tumors[1].
-
Dosage:2.5 mg/kg, 8 mg/kg, or 25 mg/kg
-
Administration:i.p.; once weekly; for 28 days
-
Result:Blocked growth of lung and ovarian cancer PDX models.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1X106 MCF-7 cells with Zenocutuzumab (HY-P99507, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Immobilized HER2/CD340 Protein, Human (HEK293, HY-P73094) can bind Zenocutuzumab. The EC50 for this effect is 2.42 ng/mL. -
Immobilized HER3 Protein, Human (HEK293, His, HY-P72625) can bind Zenocutuzumab. The EC50 for this effect is 31.77 ng/mL.
Chemical Information
-
CAS. Nr. 1969309-56-5
-
Appearance Liquid
-
Molecular Weight 145.76 kDa
-
Color Colorless to light yellow
-
SMILES
[Zenocutuzumab]
-
Synonyms
MCLA-128; PB4188; R040517
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
Reinheit & Dokumentation
-
Data Sheet (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)